



# Theranexus

SHIFTING THE LINES AGAINST  
CENTRAL NERVOUS SYSTEM  
DISORDERS



*This press release cannot be published, transmitted or distributed, directly or indirectly, in the United States, Canada, Australia or Japan. This press release does not constitute an offer to sell securities or a solicitation to purchase or subscribe for securities in the United States or any other country. Securities may only be offered, subscribed to or sold in the United States where they have been registered within the meaning of the revised U.S. Securities Act of 1933 (the "U.S. Securities Act") or where they are exempt from registration. THERANEXUS securities have not been and will not be registered in accordance with the U.S. Securities Act, and THERANEXUS does not intend to initiate a public offering of its securities in the United States.*

## Success of Theranexus' IPO on Euronext Growth in Paris

- 🌀 **Capital increase of €19.6 million**
- 🌀 **Share price set at €15.50**
- 🌀 **First day of trading: 30 October 2017**

**Lyon, 25 October 2017** – Theranexus, an innovative biopharmaceutical company that focuses on the treatment of diseases of the central nervous system, announced today the success of its initial public offering (IPO) and the upcoming listing of its shares for trading on the Euronext Growth market in Paris (FR0013286259 - ALTHX).

The IPO, carried out in connection with an open price offering (OPO) and a global placement offering (Global Placement Offering), will enable the Company to raise approximately €19.6 million through a capital increase (after fully exercising the extension clause (Extension Clause)).

This amount could be increased to approximately €21.0 million if the over-allotment option is fully exercised (Over-allotment Option).

The Global Placement Offering, primarily aimed at institutional investors, and the OPO, primarily aimed at retail investors, were both highly successful. Global subscriptions totalled 1,352,392 shares: 87% for the Global Placement Offering and 13% for the OPO, leading to an oversubscription rate of 1.2.

Theranexus' Board of Directors met earlier today and set the opening price at €15.50 per share.

Following the IPO, Theranexus' share capital now comprises 3,065,390 shares, representing a value of €47.5 million based on the opening share price. The free float accounts for 30% of the Company's share capital.

**Franck Mouthon, Chairman and Chief Executive Officer of Theranexus, said:**

*"We would like to truly thank our institutional and retail investors who have placed their trust in us during the initial public offering. We express our gratitude particularly to our long-standing shareholders who have reaffirmed their support, by fully taking part in our ambitious growth strategy. With this round of capital raising, we are going to actively continue to deploy and develop our platform and our portfolio of drug candidates."*

## ABOUT THERANEXUS

Created in 2013, THERANEXUS is a biopharmaceutical company spun off from the CEA that develops drug candidates to be used in the treatment of central nervous system (CNS) disorders. THERANEXUS has identified the major role that non-neuronal cells (or "glial cells") play in the way in which neurons respond to current CNS drugs (that only target neurons). The company creates and develops the first-ever drugs to simultaneously act on these two populations in the brain. THERANEXUS' unique, patented technology is aimed at increasing the efficacy of CNS drugs that have already been approved and are available on the market by combining them with a glial cell modulator. This strategy of combining repositioned drugs enables the company to drastically reduce the development period and development costs, while considerably increasing the likelihood of its drugs' market entry.

Proprietary, scalable and versatile, the THERANEXUS platform is used to generate high value-added proprietary drug candidates for different disorders.

THERANEXUS is supported by institutional investors (CEA Investissement, Auriga Partners, Sofimac Partners, Kreaxi).

To find out more, visit: [www.theranexus-bourse.com](http://www.theranexus-bourse.com)

### THERANEXUS

**Thierry Lambert**

Chief Administrative and Financial Officer  
[investisseurs@theranexus.fr](mailto:investisseurs@theranexus.fr)

### FP2COM

**Florence Portejoie**

Corporate Press Relations  
+33 (0)6 07 76 82 83  
[fportejoie@fp2com.fr](mailto:fportejoie@fp2com.fr)

### ACTUS finance & communication

**Théo Martin**

Investor Relations  
+33 (0)1 53 67 36 75  
[tmartin@actus.fr](mailto:tmartin@actus.fr)

### ACTUS finance & communication

**Caroline Lesage**

Investor Relations  
+33 (0)1 53 67 36 79  
[clesage@actus.fr](mailto:clesage@actus.fr)

### ACTUS finance & communication

**Alexandra Prisa**

Economic and Financial Press Relations  
+33 (0)1 53 67 36 90  
[aprisa@actus.fr](mailto:aprisa@actus.fr)

## Disclaimer

No documents or information regarding Theranexus' share (the "**Shares**") issue may be disseminated to the public in any country in which registration or approval is required. No procedures have been undertaken (nor will be undertaken) outside France, in any country in which such procedures would be required. The issue or subscription of Shares may be subject to specific legal or regulatory restrictions in certain countries. Theranexus is not liable for violations of these restrictions by any persons.

This press release is not a prospectus within the meaning of Directive 2003/71/EC of the European Parliament and the Council of November 4, 2003 as amended, in particular, by Directive 2010/73/EU of the European Parliament and the Council of November 24, 2010, as amended and transposed by each member State of the European Economic Area (the "**Prospectus Directive**").

The Offering is solely available to the French public following the AMF's approval of the Prospectus.

With respect to member states of the European Economic Area other than France that have transposed the Prospectus Directive (the "**concerned member state**"), no action has been taken nor will be taken to offer securities that would require the publication of a prospectus in any member state other than France. Consequently, the Shares may only be offered in member States: (a) to legal persons who are qualified investors as set out in the Prospectus Directive; or (b) in other cases where THERANEXUS is not required to publish a prospectus under Article 3(2) of the Prospectus Directive.

For the purposes of this paragraph, the concept of a "**public offering of Shares**" in each member State is defined as any document addressed to persons, in whatever form and by whatever means, presenting a sufficient amount of information on the terms and conditions of the Offering and on the Shares made available by the Offering, in order to enable investors to make an informed decision on purchasing or subscribing to Shares, as this concept has been, where applicable, amended in the concerned member State within the framework of the transposition of the Prospectus Directive.

This investment restriction is in addition to other restrictions applicable in member States.

The dissemination of this press release has not been carried out or approved by an "authorized person" within the meaning of Article 21(1) of the Financial Services and Markets Act 2000. Consequently, this press release is addressed to and intended solely for (i) persons located outside the United Kingdom, (ii) investment services professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, (iii) persons concerned by Article 49(2) (a) through (d) (firms with substantial equity, non-registered associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, or (iv) any other person who may be addressed by this press release in accordance with the law (the persons mentioned in paragraphs (i), (ii), (iii) and (iv) together being designated as "**Qualified Persons**"). The shares are intended solely for Qualified Persons and any invitation, offer or agreement concerning the subscription, purchase or acquisition of shares can only be addressed or entered into with Qualified Persons. Any person who is not a Qualified Person must refrain from using or relying on this press release and the information contained herein. This press release does not constitute a prospectus that has been approved by the Financial Conduct Authority or any other UK regulatory authority within the meaning of Section 85 of the Financial Services and Markets Act 2000.

This press release does not constitute an offer to sell securities or a solicitation to purchase or subscribe for securities in the United States. The securities that are the subject of this press release have not been and will not be registered within the meaning of the revised U.S. Securities Act of 1933 (the "U.S. Securities Act") and will not be offered or sold in the United States where it has not been registered with the SEC or is not exempt from registration, in accordance with the **U.S. Securities Act**. THERANEXUS does not intend to register all or part of the Offering mentioned in this press release in the United States, nor does it intend to make a public offering in the United States.

The dissemination of this press release may constitute a breach of applicable laws in certain countries. The information contained herein does not constitute an offer of securities in the United States, Canada, Australia or Japan.

This press release cannot be published, transmitted or distributed, directly or indirectly, in the United States, Canada, Australia or Japan.